跳至主要内容
临床试验/CTRI/2022/10/046891
CTRI/2022/10/046891尚未招募4 期

Efficacy and Safety of Mycophenolate Mofetil versus Oral Cyclophosphamide in Children with Frequently Relapsing or Steroid Dependent Nephrotic Syndrome: An Open Label Randomized Controlled Trial

AIIMS New Delhi0 个研究点目标入组 0 人开始时间: 待定最近更新:

试验速览

阶段
4 期
状态
尚未招募
发起方

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • Patients with idiopathic steroid sensitive nephrotic syndrome with frequent relapses or steroid dependence in the preceding 12-months and with parents willing to give informed written consent and child giving informed written assent

排除标准

  • Known secondary etiology (e.g., lupus erythematosus, IgA nephropathy, amyloidosis)
  • Initial or late steroid resistance, currently or historically
  • Therapy with oral or intravenous cyclophosphamide or MMF ever in the past
  • Therapy with cyclosporine, tacrolimus, azathioprine or rituximab in the past 6 months
  • Inability to swallow tablets or capsules of MMF
  • Impaired renal function, as indicated by eGFR <60 mL/min per 1.73 m²
  • Leukopenia, neutropenia, thrombocytopenia, elevated transaminases
  • Known chronic infection (tuberculosis, HIV, hepatitis B or C) or malignancy
  • Residing more than 100 km away or unwilling to come for regular follow-up

研究者

发起方
AIIMS New Delhi

相似试验